These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

819 related items for PubMed ID: 17132807

  • 1. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A, Carnes ML, Moon TD, Tobias R, Baade H, Stamos E, Elliott ME.
    Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
    [Abstract] [Full Text] [Related]

  • 2. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
    Malcolm JB, Derweesh IH, Kincade MC, DiBlasio CJ, Lamar KD, Wake RW, Patterson AL.
    Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
    [Abstract] [Full Text] [Related]

  • 3. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.
    Prostate Cancer Prostatic Dis; 2002 Jun; 5(4):304-10. PubMed ID: 12627216
    [Abstract] [Full Text] [Related]

  • 4. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR.
    Cancer; 2004 Mar 01; 100(5):892-9. PubMed ID: 14983482
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy.
    Tanvetyanon T.
    Cancer; 2005 Jan 15; 103(2):237-41. PubMed ID: 15597384
    [Abstract] [Full Text] [Related]

  • 8. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK, Weston R, Mistry R, Parr NJ.
    BJU Int; 2009 Sep 15; 104(6):800-5. PubMed ID: 19338564
    [Abstract] [Full Text] [Related]

  • 9. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
    Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG, Van Veldhuizen PJ, Friedman N, Reda D, Warren S, Garewal H.
    J Urol; 2009 Nov 15; 182(5):2257-64. PubMed ID: 19758618
    [Abstract] [Full Text] [Related]

  • 10. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy.
    Krupski TL, Smith MR, Lee WC, Pashos CL, Brandman J, Wang Q, Botteman M, Litwin MS.
    Cancer; 2004 Aug 01; 101(3):541-9. PubMed ID: 15274067
    [Abstract] [Full Text] [Related]

  • 11. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
    Galvão DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, Rowling C, Prince R.
    BJU Int; 2008 Jul 01; 102(1):44-7. PubMed ID: 18336606
    [Abstract] [Full Text] [Related]

  • 12. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
    Ryan CW, Huo D, Stallings JW, Davis RL, Beer TM, McWhorter LT.
    Urology; 2007 Jul 01; 70(1):122-6. PubMed ID: 17656221
    [Abstract] [Full Text] [Related]

  • 13. Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.
    Morabito N, Gaudio A, Lasco A, Catalano A, Atteritano M, Trifiletti A, Anastasi G, Melloni D, Frisina N.
    J Bone Miner Res; 2004 Nov 01; 19(11):1766-70. PubMed ID: 15476575
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The relationship between daily calcium intake and bone mineral density in men with prostate cancer.
    Planas J, Morote J, Orsola A, Salvador C, Trilla E, Cecchini L, Raventós CX.
    BJU Int; 2007 Apr 01; 99(4):812-5; discussion 815-6. PubMed ID: 17378843
    [Abstract] [Full Text] [Related]

  • 16. Osteoporosis during androgen deprivation therapy for prostate cancer.
    Smith MR.
    Urology; 2002 Sep 01; 60(3 Suppl 1):79-85; discussion 86. PubMed ID: 12231056
    [Abstract] [Full Text] [Related]

  • 17. Oral bisphosphonate prevents bone loss in androgen deprivation therapy for nonmetastatic prostate cancer.
    Kawahara T, Kobayashi T, Nishizawa K, Kobori G, Mitsumori K, Ogura K.
    Hinyokika Kiyo; 2008 Apr 01; 54(4):261-6. PubMed ID: 18516917
    [Abstract] [Full Text] [Related]

  • 18. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy.
    Bruder JM, Ma JZ, Basler JW, Welch MD.
    Urology; 2006 Jan 01; 67(1):152-5. PubMed ID: 16413352
    [Abstract] [Full Text] [Related]

  • 19. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
    Ishizaka K, Machida T, Kobayashi S, Kanbe N, Kitahara S, Yoshida K.
    Int J Urol; 2007 Dec 01; 14(12):1071-5. PubMed ID: 18036042
    [Abstract] [Full Text] [Related]

  • 20. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.
    Smith MR.
    Oncology (Williston Park); 2004 May 01; 18(5 Suppl 3):21-5. PubMed ID: 15202584
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.